Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sentinel May Expand To Generic Equivalence Studies

Executive Summary

Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.


Related Content

Sentinel Offers Drug Firms ‘Unique’ Venue For Post-Market Studies, Pfizer Says
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error
Sentinel’s “IMPACT” Beyond Safety: Anti-Coagulant Study Is Early Test
FDA Aims To Tap Sentinel Data Network For Drug Effectiveness Studies
Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA
Generic Labeling Rule Becomes Statistical Battle As Public Meeting Looms
FDA Bioequivalence Study On Metoprolol Shows Emerging Generic Investigation Strategy
FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts